About us:

Neoflow Technologies Ltd. develops novel endovascular solution for the treatment of vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH).

Vasospasm is a critical condition leading to Delayed Ischemic Neurological Deficit (DIND) and counts as the major complication of aneurysmal Subarachnoid Hemorrhage (aSAH) in ~40% of all cases.

Nowadays, treatment divides into two approaches as follows,  the pharmacological approach and the balloon angioplasty treatment. Pharmacological effectiveness is questioned due to the limitations and associated risks. Administration of vasodilators leads to a Blood Pressure drop, which is restricted to a specific group of patients, while Triple H treatment imposes the risk of additional aneurysmal bursting. While the balloon angioplasty treatment effectiveness is strict, associated risks of blood vessel rupture and atherosclerosis plaque fracture embolization keep the treatment out of common practice in some of the leading neurovascular centers around the globe.

There is no safe & effective solution for the treatment of aSAH. NeoFlow is addressing this critical unmet need.


We are aiming to make a widely accessible simple design endovascular device for the treatment of vasospasm. The Vasoconstriction relief should be achieved by a humble local manipulation, reducing the angioplasty and systemic pharmacology risks.


The market

The general incidence of aSAH stands at 9.2/100,000 worldwide. Nearly half of the aSAH patients will suffer from symptomatic vasospasm, and approximately 2/3 of the vasospasm patients will require active intervention to treat the acute symptoms.

The vasospasm complication direct hospitalization costs the US health system stands on 1.5B USD in total, which is on average an additional 40K USD per patient.



David Skorohod, Co-founder and CEO

Vast experience in R&D, Operations and QA management, from prototype to market, to acquisition.

More than a decade of experience with the development of medical technology in neurosurgical and endovascular fields.

Limor Sandach, co-founder and BD

Senior Executive with over 25 years of experience in investment in healthcare innovation and management of startups in MedTech.


Maroun Farah, Co-Founder and Industry specialist

Industry specialist with extensive experience in the field of neurological research and development.


Contact Info:

David Skorohod, CEO


POB 1252, Nazareth, 1711102, Israel